Literature DB >> 26316081

MiR-497 Suppresses YAP1 and Inhibits Tumor Growth in Non-Small Cell Lung Cancer.

Chongbiao Huang1, Ruijue Ma, Jie Yue, Na Li, Zengxun Li, Daliang Qi.   

Abstract

BACKGROUND/AIMS: To investigate the expression, clinical significance and the cellular effects of miR-497 in non-small cell lung cancer (NSCLC).
METHODS: NSCLC cells were transiently transfected with miR-497 mimics or siRNA to up-regulate or down-regulate expression. Quantitative real-time PCR (qRT-PCR) was used to detect the mRNA level of miR-497. Luciferase assays, colony formation assays and BrdU incorporation assays were performed to identify the targets and role of miR-497 in NSCLC cells. Finally, the abundance of miR-497 was analyzed in a total of 51 NSCLC specimens.
RESULTS: The transcript levels of miR-497 were significantly decreased in NSCLC tissue (25/30; 83.3%). Low miR-497 levels in tumor tissue correlated with advanced pT stage. Additionally, miR-497 transcript levels correlated with overall survival of NSCLC patients (n = 51, p = 0.022). Overexpression of miR-497 inhibited the proliferation of NSCLC cell and down-regulation of miR-497 resulted in elevated NSCLC growth. Exogenous over-expression of YAP1 partially eliminated miR-497-induced cell growth.
CONCLUSION: miR-497 plays an important role in inhibiting the proliferation of NSCLC by targeting YAP1. Our results suggest that miR-497 is a potential therapeutic target in treating patients with NSCLC.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26316081     DOI: 10.1159/000430358

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  19 in total

1.  PLOD3 regulates the expression of YAP1 to affect the progression of non-small cell lung cancer via the PKCδ/CDK1/LIMD1 signaling pathway.

Authors:  Wei-Hao Li; Kai Huang; Feng-Biao Wen; Guang-Hui Cui; Hai-Zhou Guo; Song Zhao
Journal:  Lab Invest       Date:  2022-01-17       Impact factor: 5.662

2.  miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug.

Authors:  Zhihao Wu; Xiangli Li; Xuehong Cai; Chenggang Huang; Min Zheng
Journal:  Tumour Biol       Date:  2015-12-23

Review 3.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

4.  The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex.

Authors:  Lorena Verduci; Maria Ferraiuolo; Andrea Sacconi; Federica Ganci; Jlenia Vitale; Teresa Colombo; Paola Paci; Sabrina Strano; Giuseppe Macino; Nikolaus Rajewsky; Giovanni Blandino
Journal:  Genome Biol       Date:  2017-12-20       Impact factor: 13.583

5.  MicroRNA‑497 inhibits cellular proliferation, migration and invasion of papillary thyroid cancer by directly targeting AKT3.

Authors:  Juhua Zhuang; Ying Ye; Guoyu Wang; Jing Ni; Saifei He; Cuihua Hu; Wei Xia; Zhongwei Lv
Journal:  Mol Med Rep       Date:  2017-08-24       Impact factor: 3.423

6.  miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP.

Authors:  Min Ho Choe; Yina Yoon; Joon Kim; Sang-Gu Hwang; Young-Hoon Han; Jae-Sung Kim
Journal:  Cell Death Dis       Date:  2018-05-29       Impact factor: 8.469

7.  miR-145 and miR-497 suppress TGF-β-induced epithelial-mesenchymal transition of non-small cell lung cancer by targeting MTDH.

Authors:  Qi Yin; Yang Han; Dongyi Zhu; Zhanxia Li; Shan Shan; Wenjing Jin; Qingchun Lu; Tao Ren
Journal:  Cancer Cell Int       Date:  2018-07-27       Impact factor: 5.722

8.  miR-497 inhibited proliferation, migration and invasion of thyroid papillary carcinoma cells by negatively regulating YAP1 expression.

Authors:  Hui Cheng; Hui Dong; Jianlin Feng; Hongyan Tian; Haixia Zhang; Lina Xu
Journal:  Onco Targets Ther       Date:  2018-08-10       Impact factor: 4.147

Review 9.  MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.

Authors:  Irina Fadejeva; Horst Olschewski; Andelko Hrzenjak
Journal:  Oncotarget       Date:  2017-12-05

Review 10.  miR-497 expression, function and clinical application in cancer.

Authors:  Gang Yang; Guangbing Xiong; Zhe Cao; Suli Zheng; Lei You; Taiping Zhang; Yupei Zhao
Journal:  Oncotarget       Date:  2016-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.